Our study also validated SOX5 as a promising therapeutic target by demonstrating that SOX5 inhibition in combination with PARP inhibitor shows synergistic anticancer activity in PARP inhibitor-resistant preclinical cancer models. The gene discussed is SOX5; the disease is cancer.